| ID | JOS-fddev.2023.1150894 |
| 著者：名前 | |
| 著者：別形式 | Ito, Ayu / Itakura, Shoko / Hasegawa, Yuya / Hashimoto, Miyu/ Okada, Akie / Hirafuji, Mamoru / Nakamura, Hidenori / Sugibayashi, Kenji / Todo, Hiroaki |
| 著者：カナ | |
| 著者：所属 | 城西大学薬学部 / 城西大学薬学部 / 城西大学薬学部 / 城西大学薬学部 / 城西大学薬学部 / アットドウス株式会社 / アットドウス株式会社 / 城西国際大学薬学部 / 城西大学薬学部 |
| 著者：所属(別形式） | Josai University, Faculty of Pharmacy and Pharmaceutical Sciences / Josai University, Faculty of Pharmacy and Pharmaceutical Sciences / Josai University, Faculty of Pharmacy and Pharmaceutical Sciences / Josai University, Faculty of Pharmacy and Pharmaceutical Sciences/ Josai University, Faculty of Pharmacy and Pharmaceutical Sciences / atDose Co., Ltd. / atDose Co., Ltd. / Josai International University, Faculty of Pharmaceutical Sciences / Josai University, Faculty of Pharmacy and Pharmaceutical Sciences |
| 著者版フラグ | publisher |
| 出版地 | Lausanne |
| 出版者 | Frontiers |
| 電子ISSN | 26740850 |
| 掲載誌名 | |
| 巻 | 3 |
| 刊行年月 | 2023-04 |
| 開始ページ | 1 |
| 終了ページ | 8 |
| コンテンツ作成日 | 2023-01-25 |
| コンテンツ修正日 | 2023-03-24 |
| コンテンツ登録日 | 2023-05-31 |
| 識別番号：DOI | info:doi/10.3389/fddev.2023.1150894 |
| 識別番号：DOI（リンク） | |
| 抄録 | Patients receiving chemotherapy by intravenous (i.v.) or oral administration of anticancer drugs often experience side effects. In this study, an electro-osmotic flow (EO) pump was used for the direct administration of an anticancer drug with minimum side effects. Doxorubicin hydrochloride (DXR) was used as an anticancer drug, and its antitumor effect and toxicity were evaluated in comparison with i.v. administration. Balb/c femalemice were subcutaneously transplanted with a breast cancer cell line (4T1/Luc) stably expressing luciferase, and 20 μL of DXR solution (1.0mg/mL)was administered intratumorally (i.t.) at a slowrate (0.6 μL/min) using an EO pump or rapidly using a syringe. For comparison, 100 μL of DXR solution was injected through the tail vein at the same dose and a 5-times higher dose. A tumor growth inhibitory effect without significant weight loss was observed with direct i.t. administration of DXR using an EO pump. On the other hand, no suppressive tumor growth effect was observed with i.v. administration of DXR at the same dose. Although there was no significant difference in the suppression effect on tumor growth between i.t. administration with EO pump and syringe, the peripheral skin concentration of DXR were decreased after slow administration with EO pump compared with that after rapidly administration with a syringe. These results indicated that direct i.t. administration of DXR with lower dosing using an EO pump at slower administration rate may be useful for exhibiting antitumor effects and suppressing systemic side effects. In addition, the blood concentration and the peripheral skin concentration of DXR after administration at lower rate with EO pump were decreased compared with those after the rapidly administration with a syringe. |
| キーワード | |
| 注記 | p.8 This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| 言語 | eng |
| 資源タイプ | text |
| ジャンル | |
| フォーマット | application/pdf |
| 権利 | Copyright © 2023 Ito, Itakura, Hasegawa, Hashimoto, Okada, Hirafuji, Nakamura, Sugibayashi and Todo. |
| このアイテムを表示する：本文(pdf) |  ダウンロード回数： 回 |
| このアイテムを表示する：URI | |
